Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
16 /100
LOW RISK
Score updated Jul 28, 2026

SBMFF — Sino Biopharmaceutical Limited Dilution Risk Tracker

Track SBMFF dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track SBMFF — Get alerts when the score changes →

As of July 28, 2026, Sino Biopharmaceutical Limited (SBMFF) has a DilutionWatch DilutionScore of 16/100, rated LOW dilution risk. Sino Biopharmaceutical Limited has a market capitalization of $13.87B, 17.84B shares outstanding.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
18
💰 Cash Runway
10
📊 Float Risk
27
⚠️ Warrant Exposure
15
🔄Convertible Debt

Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
27%
🔄 Reverse Split 55%
• 50-day avg $0.74 below $1 exchange minimum
🔔 Track SBMFF — Get forecast alerts →

Market Data

Market Cap$13.87B
Shares Outstanding17.84B
Float8.77B
Cash$3.39B
Debt$2.38B
Short InterestN/A

Institutional Holdings

22.0% institutional ownership
Source: Yahoo Finance · Detailed 13F holder data available for tracked tickers
🔔 Track SBMFF for full holder detail →

Short Interest

Short Interest54.22M
Days to Cover1000.0
% of Float0.6%
FINRA data as of Jul 15, 2026

Recent SEC Activity

No recent SEC insights

Recent News

No recent news

What This Means for SBMFF Shareholders

Sino Biopharmaceutical Limited (SBMFF) has a DilutionScore of 16/100, rated Low dilution risk. At this score level, DilutionWatch's real-time EDGAR monitoring shows limited near-term dilution signals. This does not mean zero dilution risk — shelf registrations can be filed and activated quickly — but the current filing profile shows no major outstanding dilution programs. Score as of July 28, 2026.

DilutionWatch's EDGAR monitoring for SBMFF shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for SBMFF in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for SBMFF alongside comparable low-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding SBMFF's Dilution Risk Factors

Primary Risk Drivers

The most significant dilution risks for Sino Biopharmaceutical Limited stem from its Offering Ability and Cash Runway scores. Offering Ability is currently at a level that indicates moderate potential for new equity issuance, which directly increases the total number of shares outstanding. The Cash Runway score reflects a low cash reserve situation, indicating that the company may be inclined to raise capital through equity offerings rather than debt or internal accruals. These two factors together suggest that if the company needs funding, it could easily dilute existing shareholders through new share issuance.

Factors Currently Not a Concern

The Float Risk and Warrant Exposure scores are both low, suggesting minimal risk from large-scale trading activity or warrant conversions. The Convertible Note Risk is also low, indicating that any convertible debt held by third parties does not pose an immediate dilution threat. However, changes in SEC filings such as the issuance of new warrants or a significant increase in outstanding convertible notes could quickly elevate these scores. Additionally, if the company begins to issue more shares under existing equity incentive plans, Float Risk could rise sharply.

SEC Filings to Watch

Key filings to monitor include S-3 registration statements, which signal potential large-scale equity offerings; 424B5 documents, often used for shelf offerings that can be quickly activated; and 8-K Item 1.01 announcements, which disclose new equity issuances or significant corporate actions. Quarterly reports (10-Q) are also critical as they reveal changes in capital structure, including any newly issued shares or modifications to equity incentive plans. These filings provide early signals of whether the company is preparing to raise additional capital through dilutive means.

How Dilution Happens

Dilution occurs when a company issues new shares, increasing the total number of outstanding shares and thereby reducing the ownership percentage of existing shareholders. For SBMFF, if Offering Ability is high, it could issue new stock in response to cash needs. If Cash Runway is low, this pressure to raise capital is more acute. The process typically begins with a board resolution or regulatory filing, followed by a public offering or private placement. Each share issued in such a transaction dilutes the value of existing holdings, reducing earnings per share and potentially diminishing investor returns.

What Would Make This Worse

A significant deterioration in SBMFF’s risk profile could occur if the company enters into multiple convertible note agreements or issues warrants that convert into equity at low prices. Additionally, if a large portion of its float becomes subject to rapid trading due to a major shareholder selling or if it initiates a large equity incentive plan, the dilution pressure would increase. A drop in cash reserves combined with an inability to secure debt financing could force the company into more frequent and larger equity offerings, thereby accelerating share dilution.

Key Insight

Despite low scores, SBMFF’s Offering Ability and Cash Runway are key indicators of potential future dilution risk that should be monitored closely through SEC filings.

How to Monitor SBMFF for Dilution Risk

What This Risk Level Means

For a large-cap operating company like Sino Biopharmaceutical Limited (SBMFF), a low dilution risk score indicates that the firm is currently well-protected from significant equity dilution. As a large-cap entity, SBMFF has established financial stability and typically operates with a more conservative capital structure. The absence of elevated factors suggests that management has not engaged in practices that would significantly increase shareholder ownership dilution, such as frequent equity issuances or warrant programs. This score reflects a stable financial environment where the company’s existing shareholders are not under immediate pressure from dilutive actions.

What Typically Happens Next

Companies at this profile often maintain their current capital structure unless strategic opportunities arise, such as new product launches or expansion initiatives. While large-cap firms rarely initiate shelf registrations or ATM programs, they may occasionally issue equity for specific purposes like acquisitions or debt refinancing. For SBMFF, a typical progression would involve careful capital management and possibly limited use of warrants or other equity instruments to fund operations. Monitoring for any sudden issuance activity is critical, as even low-risk companies can shift quickly if financial pressures arise.

Monitoring Playbook

To effectively track dilution risk for SBMFF, use DilutionWatch to set up alerts for any changes in dilution metrics. Check the company’s filings monthly and monitor for new equity offerings or warrant exercises. Set a threshold at 30/100 for any individual dilution factor to trigger an immediate review. If a score exceeds this, investigate the underlying cause — such as a new equity offering or a change in warrant terms. The Shelf & ATM Monitor can also be used to track potential upcoming equity issuances that may not yet be reflected in the DilutionWatch score.

Early Warning Signals

Several specific signals indicate a worsening dilution profile. First, an increase in the number of outstanding warrants or new warrant issuances would raise red flags. Second, any mention of equity-based compensation increases or stock option grants in SEC filings may suggest future dilution. Third, changes in share count or the introduction of new equity programs such as ATM offerings are strong indicators that the company is preparing to issue more shares, increasing dilution risk.

What a Positive Resolution Looks Like

A positive shift in SBMFF’s dilution profile would occur if the company undertakes a capital raise that strengthens its balance sheet, or if existing warrants expire without exercise. A reduction in outstanding equity instruments or a decrease in the frequency of equity-based compensation would also improve the score. Additionally, any debt paydown or repurchase program that reduces the need for further equity issuance could signal a healthier financial stance and lower dilution risk.

Watch For

Unusual warrant activity or equity issuance announcements in SEC filings, particularly those not tied to strategic initiatives.

Full SEC filing analysis available with free account  →
Track SBMFF Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking SBMFF — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — LOW Risk

Other LOW dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for SBMFF
SBMFF Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.